The Community Focus Channel is supported with funding from Johnson & Johnson (Gold).
The Multiple Myeloma Channel is supported with funding from Sanofi (Gold) and Legend Biotech (Bronze).
VJHemOnc is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
ASH 2025 | HRQoL with belantamab mafodotin treatment in patients with R/R myeloma in the DREAMM-7 trial
Sagar Lonial, MD, Winship Cancer Institute of Emory University, Atlanta, GA, discusses the health-related quality of life (HRQoL) of patients with relapsed/refractory (R/R) multiple myeloma receiving belantamab mafodotin in the DREAMM-7 trial (NCT04246047). Prof. Lonial highlights that despite concerns about ocular events, the data show that HRQoL improved over time for patients treated with the agent, and the impact of therapy on daily activities was limited. This interview took place at the 67th ASH Annual Meeting and Exposition, held in Orlando, FL.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
Transcript
One of the really nice things about DREAMM-7 and DREAMM-8 is that they did fairly extensive quality of life instruments associated with treatments in both arms. And so what I really enjoyed about this data set was that it gave us a pretty comprehensive view of what was going on. And while there were some impact on visual acuity and things like reading or driving, they were fairly limited and actually the quality of life over time actually improved for patients who were on belamaf...
One of the really nice things about DREAMM-7 and DREAMM-8 is that they did fairly extensive quality of life instruments associated with treatments in both arms. And so what I really enjoyed about this data set was that it gave us a pretty comprehensive view of what was going on. And while there were some impact on visual acuity and things like reading or driving, they were fairly limited and actually the quality of life over time actually improved for patients who were on belamaf. And given that there are so many people talking about the ocular events and side effects, it’s very reassuring that when you hear from the patients who were on a randomized phase three trial, they actually described their quality of life as being better over time compared to the control arm.
You know, with belantamab mafodotin, the big concern by both patients and doctors is the ocular issues, the microcysts that occur. And what we know about this from a large number of patients that have been treated now is that it does always reverse. And one of the little quirks in the grading system is that there are two ways to evaluate ocular events. The first is an ophthalmologist looking at the cornea and counting the number of dots or where the dots are. The second is looking at a Snellen eye chart and being able to read. You pick the worst of those two and that’s the grading. So it’s not uncommon to see grade two events where patients have no impact at all on their ability to read or drive. And so that dichotomy is really important for patients to understand.
This transcript is AI-generated. While we strive for accuracy, please verify this copy with the video.
Read more...
